Physician profile
Karly G Neff
NPI 1609465483
$4,876.18
in general payments reported to CMS, 2019-2025
36 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,136 · 2022: $858 · 2024: $1,175 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $759.06 | 2021-2025 | |
| Janssen Biotech, INC. | $400.63 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.33 | 2021-2024 | Spevigo |
| Novo Nordisk INC | $254.96 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $237.28 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $232.70 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $228.46 | 2024-2025 | |
| Lilly USA, LLC | $221.36 | 2021-2025 | Ebglyss |
| Galderma Laboratories, L.P. | $205.74 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $190.42 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $186.28 | 2022 | |
| Amarin Pharma, INC. | $166.82 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $159.41 | 2021-2022 | |
| Ucb, INC. | $151.43 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $133.58 | 2024-2025 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.48 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $109.34 | 2024-2025 | |
| Pfizer INC. | $93.90 | 2021-2024 | |
| Glaxosmithkline, LLC. | $93.73 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $89.92 | 2021-2024 | Sotyktu |
| Incyte Corporation | $86.32 | 2025 | Opzelura |
| Merck Sharp & Dohme LLC | $60.00 | 2021-2022 | |
| Almirall LLC | $56.70 | 2024-2025 | Seysara |
| Convatec INC. | $54.97 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $50.32 | 2021 | |
| Vanda Pharmaceuticals INC. | $39.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $38.31 | 2021-2022 | |
| Amgen INC. | $37.81 | 2024 | Otezla |
| Sunovion Pharmaceuticals INC. | $35.11 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.78 | 2022 | |
| Botanix Sb INC | $19.45 | 2025 | Sofdra |
| Takeda Pharmaceuticals U.S.A., INC. | $17.79 | 2021 | |
| Dermavant Sciences, INC. | $15.67 | 2024 | Vtama |
| Currax Pharmaceuticals LLC | $13.97 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.42 | 2022 | |
| Medtronic, INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karly Neff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.